- U.S. says it wants Syrian government to negotiate 'seriously' with opp
- Star Wars: The Last Jedi Spoilers: Who Are Rey's Parents?
- Zimbabwe's ruling party must fix economy to win vote: president
- Victims of Mexico military abuses shudder at new security law
- Trump to propose ending rule allowing spouses of H-1B holders to work in U.S.
- GameSpot's Best Games Of 2017 #6: Horizon: Zero Dawn
- Star Wars: The Last Jedi Review - Is It Any Good?
- Man with knife shot at Amsterdam airport; suspect is known offender
- Tillerson urges long halt to North Korea weapons tests before any talk
- Phone-based therapy sessions may help dementia caregivers cope
- Far Cry 5 Gameplay Showcases The Series' Familiar Insanity
- Peru lawmakers file motion to impeach president Kuczynski
- Brazil's Temer says pension bill 2 to 3 dozen votes short
- Free PUBG Included With Xbox One X For A Limited Time
- Fed's Quarles to recuse himself from Wells Fargo matters
- Star Wars: The Last Jedi Spoilers: Who Is Snoke?
- Supporters of Hungarian Jobbik opposition party protest over crackdown
- Sports sector wins reprieve in EU copyright reform
- Tobacco industry trumps as India court cancels stringent health labeli
- Destiny 2 Xur Location Guide: Where Is Xur And What Is He Selling? (December 15-18)
Shire in deal to develop a new way to administer hemophilia drug
(Reuters) - Shire Plc said on Tuesday it had partnered with a California-based company to develop a new way to administer a drug to treat hemophilia A.
The company, Rani Therapeutics, has developed a technology that will help oral delivery of peptides, proteins and therapeutic antibodies which to date could be delivered only through injections.
Once delivered through Rani Pill - the oral delivery technology - the drug stays in the body until it enters the small intestine and transfers the medicine into the intestinal wall, the companies said.
The method does not expose the medication to digestive enzymes and is also expected to be pain free, since the intestines do not have sharp pain receptors, the companies said.
Shire, which made an equity investment in Rani, has the option to negotiate a licensing deal to develop and market the drug delivery approach, after completion of certain studies.
Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.
Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila
Our Standards:The Thomson Reuters Trust Principles.